

University of Parma Research Repository

Differential Catabolism of an Anthocyanin-Rich Elderberry Extract by Three Gut Microbiota Bacterial Species

This is the peer reviewd version of the followng article:

Original

Differential Catabolism of an Anthocyanin-Rich Elderberry Extract by Three Gut Microbiota Bacterial Species / Bresciani, Letizia; Angelino, Donato; Vivas, Eugenio I; Kerby, Robert L; García-Viguera, Cristina; Del Rio, Daniele; Rey, Federico E; Mena, Pedro. - In: JOURNAL OF AGRICULTURAL AND FOOD CHEMISTRY. -ISSN 0021-8561. - 68:7(2020), pp. 1837-1843. [10.1021/acs.jafc.9b00247]

Availability: This version is available at: 11381/2859546 since: 2020-03-24T17:09:36Z

Publisher: American Chemical Society

Published DOI:10.1021/acs.jafc.9b00247

Terms of use:

Anyone can freely access the full text of works made available as "Open Access". Works made available

Publisher copyright

note finali coverpage

1 Differential catabolism of an anthocyanin-rich elderberry extract by three gut

2 microbiota bacterial species

- 3 Letizia Bresciani^{1,#}, Donato Angelino^{2,#}, Eugenio Vivas³, Robert Kerby³, Cristina García-Viguera⁴,
- 4 Daniele Del Rio^{1,2,5}, Federico E. Rey ^{3,*}, Pedro Mena ^{2,*}
- 5
- ⁶ ¹ Laboratory of Phytochemicals in Physiology, Department of Veterinary Science, University of
- 7 Parma, 43125 Parma, Italy.
- 8 ² Laboratory of Phytochemicals in Physiology, Department of Food & Drugs, University of Parma,
- 9 43125 Parma, Italy.
- ³ Department of Bacteriology, University of Wisconsin, 53706 Madison, Wisconsin, US
- ⁴ Phytochemistry and Healthy Food Lab, Department of Food Science and Technology, CEBAS-CSIC,
- 12 Campus de Espinardo, 30100 Murcia, Spain.
- ⁵ Microbiome Research Hub, University of Parma, 43124 Parma, Italy
- 14 *#* Equal contribution as first author.
- 15

16 ***Correspondence**:

- 17 Pedro Mena, Human Nutrition Unit, Department of Food & Drugs, University of Parma, Medical
- School Building C, Via Volturno, 39, 43125 Parma, Italy. Phone: +39 0521-903841. E-mail:

19 <u>pedromiguel.menaparreno@unipr.it</u>.

- 20 Federico Rey, Department of Bacteriology, University of Wisconsin-Madison, WI, United States.
- 21 Phone: +1 608-890-2046 E-mail: ferey@wisc.edu.
- 22
- -
- 23
- 24

25 ABSTRACT

Elderberries are good sources of anthocyanins, which are poorly absorbed in the upper 26 gastrointestinal tract but extensively transformed into phenolic metabolites at colonic level. Since 27 different gut microbiota strains have different metabolism, the catabolism of anthocyanins may lead 28 to inter-individual differences in metabolite production. In this work, an anthocyanin-rich elderberry 29 30 extract was incubated with three single gut microbial strains (Enterobacter cancerogenous, Bifidobacterium dentium and Dorea longicatena) up to four days, to assess differences in their 31 32 phenolic metabolism. All the strains degraded the elderberry anthocyanins, but the metabolic pathways followed were different. Although some metabolites were common for all the strains, a 33 wide disparity was observed in the kind and in the amount of several phenolic metabolites produced 34 35 by each species. These in vitro preliminary results may be of help in the interpretation of the bioavailability of anthocyanins and give a clue to understand inter-individual variability in 36 metabolite production. 37

38

39 KEYWORDS (3 to 5)

40 Anthocyanin; phenolic acids; gut microbiota; metabolism; inter-individual variability.

41 **INTRODUCTION**

Anthocyanins are a group of phenolic compounds responsible for the red-orange to blue-violet color 42 shades of fruits and vegetables.¹ Cyanidin, peonidin, delphinidin, malvidin, petunidin, and 43 pelargonidin glycosides are the most common anthocyanins distributed in plants.^{2,3} Significant 44 sources of anthocyanins are berries (i.e. blueberries, mulberries, blackberries, elderberry, 45 strawberries), red grapes, wine, and pomegranate. ⁴ Epidemiological and intervention studies have 46 confirmed that the consumption of anthocyanin-rich foods is associated with a decreased risk of 47 cardiovascular diseases,^{5–7} an improvement of the antioxidant status,^{8,9} and an amelioration of 48 cognitive performance in impaired individuals.^{10,11} Despite their biological effects, pharmacokinetic 49 studies have demonstrated poor absorption in the upper gastrointestinal tract¹² and a very low 50 bioavailability of anthocyanins, ranging from 0.5% to 1% of the ingested dose.^{13,14} Particularly, it has 51 been showed that they undergo an extensive decomposition in the colonic tract by gut microbiota.¹⁵ 52 Intriguingly, it has been suggested that different strains as well as different substituents on the A-, 53 B-, C-rings of the flavylium cation might have a role in driving different breakdown pathways of the 54 anthocyanin structure.¹⁶ The first pioneering work concerning anthocyanin incubation with human 55 fecal inocula indicated very low amounts of the single aglycons after 24-h fermentation.¹⁷ 56 57 Conversely, despite different compounds have been hypothesized to derive from A-ring breakdown, namely phloroglucinol and its aldehyde, resorcinol,^{15,17,18} and ferulic acid,¹⁸ B-ring structure is more 58 prone to the microbiota-mediated transformations. González-Barrio et al.¹⁵ hypothesized that the 59 microbial cyanidin B-ring-derived compounds are mainly phenolic acids, as mono- and di-60 hydroxybenzoic, mono- and di-hydroxyphenylpropionic, and mono- and di-hydroxyphenylacetic 61 62 acids, among others.¹³ Unfortunately, the use of fecal inocula does not allow clear elucidation of which and how the single gut bacteria strains can access and modify the structure of anthocyanins. 63 Moreover, the metabolic fate of the anthocyanin-derived compounds cannot be drawn by the 64

rearrangements of different strains present into the inoculum. In the present work, three different anaerobic gut microbial strains, namely *Enterobacter cancerogenous* (EC), *Bifidobacterium dentium* (BD), and *Dorea longicatena* (DL), were individually incubated with an anthocyanin-rich elderberry extract with the goal of identifying and quantifying anthocyanins and their metabolic derivative compounds. This will shed light on the contribution of different bacteria strains to the formation of anthocyanin-derived metabolites.

71

72 MATERIAL AND METHODS (≤ 500 words)

73 Chemicals

All chemicals and solvents were of analytical grade. All solvents were purchased from Sigma-Aldrich 74 75 (St. Louis, MO, USA). Cyanidin-3-glucoside, pyrogallol, 3,4-dihydroxybenzoic acid (protocatechuic 76 acid), 3,4-dihydroxybenzaldehyde, 2-(4'-hydroxyphenyl)acetic acid, 3-hydroxybenzoic acid, 4hydroxybenzaldehyde, 4-methoxybenzaldehyde, 3-(3'-hydroxyphenyl)propionic acid, and 3-77 hydroxycinnamic acid (m-coumaric acid) were purchased from Sigma-Aldrich. 2-(4'-Hydroxy-3'-78 79 methoxyphenyl)acetic acid (homovanillic acid) was purchased from Extrasynthese (Genay Cedex, France). Ultrapure water from MilliQsystem (Millipore, Bedford, MA, USA) was used throughout the 80 81 experiment.

82 Cell Culture

Anaerobic cultures were prepared using filter-sterilized "MML" medium (Supplementary Table S1) amended with 2% elderberry extract (*Sambucus nigra* L., DDW WS35, Port Washington, WI, USA). Tubes were inoculated (0.5 mL inoculum into 10 mL medium) with freshly-grown cultures prepared in the same medium supplemented with 10 mM glucose and 5-fold increased levels of tryptone, yeast extract and meat extract—of *Bifidobacterium dentium* ATCC 27534, *Dorea longicatena* DSMZ 13814 or *Enterobacter cancerogenous* ATCC 36316 (kindly supplied by J. Gordon,

89 Washington University, St. Louis, MO, USA), or left uninoculated as a control, then incubated at 90 37°C. Strains were chosen based on pilot experiments where these strains differentially degraded 91 elderberry anthocyanins into 3,4-dihydroxybenzoic acid (protocatechuic acid, Supplementary Figure 92 S1). In particular, DL and BD produced high and moderate amounts of protocatechuic acid, 93 respectively, while EC degraded the amount of protocatechuic acid in the extract (Supplementary 94 Figure S1). Samples (1.0 mL) were obtained using sterile 75% N₂ / 20% CO₂ / 5% H₂-flushed syringes, injected into 128 µL of 88% formic acid, chilled on ice, centrifuged to pellet cells, then 0.2 µm-filtered 95 96 and stored at -80°C prior to analysis. Cultures derived from a single flask were assayed for each time 97 point.

98 Sample preparation and UHPLC-MS/MS and –MSⁿ analyses

99 Cell media were extracted according to Sala et al.¹⁹, but using acidified methanol (0.1% formic acid) 100 instead of pure methanol. Samples were analyzed for quantification purposes by UHPLC DIONEX Ultimate 3000 equipped with a TSQ Vantage triple quadrupole mass spectrometer (Thermo Fisher 101 Scientific Inc., San Jose, CA, USA), as fully reported in Brindani et al.²⁰ The tentative identification of 102 some compounds was carried out using targeted full MS² experiments with the same instrument 103 104 and analytical conditions. Quantification was performed with calibration curves of standard 105 compounds, when available. When not available, the metabolites were quantified with the most 106 similar compound in terms of molecular weight and structure.

107 Targeted full MS³ experiments were carried out in order to confirm the identity of some 108 anthocyanins. Experiments were carried out using an Accela UHPLC 1250 equipped with a linear ion 109 trap-mass spectrometer (MS) (LTQ XL) fitted with a heated-electrospray ionization (ESI) probe 110 (Thermo Fisher Scientific Inc.). Analytical details are provided at Supplementary Method S1.

111 Statistical analysis

The SPSS statistical package (SPSS Inc., Chicago, IL, USA, version 25) was used. Analyses were performed in triplicate. All data were expressed as mean ± SD. One-way ANOVA with Tukey HSD *post hoc* tests were carried out. Principal component analysis (PCA) with varimax was performed to explore the variability among bacterial strains at different time points.

116

117 **RESULTS AND DISCUSSION**

The set of compounds targeted and/or identified, and their spectrometric characteristics are 118 119 presented in Table 1. Thirty compounds related to the anthocyanin profile of the elderberry extract (compounds 1, 2, 3, 4, 5, and 6) and to the putative degradation pathway of elderberry anthocyanins 120 (7-20, 22, 24, 25-29, 33, 34 and 35) were targeted by considering previous reports.^{15,18,21,22} Eleven 121 122 out of the 30 compounds were not found in the cultured samples (11, 12, 14-17, 24, 27, 29, 34, and 123 35), while up to 6 unexpected peaks were observed in the chromatograms (compounds 21, 23, 30-32, and 36). Peak areas for these non-targeted compounds changed in comparison with the 124 uninoculated control medium and depending on the bacteria strains and time points, so they were 125 126 considered to be potential isomers of the targeted metabolites derived from anthocyanin 127 catabolism. However, although additional commercial standards were run and further ad hoc full 128 MS² target experiments were carried out and compared with literature, only compounds 21 and 30 could be identified. Chromatographic and MS² spectra data for these unidentified compounds are 129 130 reported in Table 1. Similarly, additional experiments were carried out in order to fully confirm the presence of peonidin glycosides (5 and 6) in the elderberry extract used. Although Olejnik et al.²³ 131 reported the presence of these two compounds in an elderberry extract at trace levels, their 132 133 presence in elderberry contrasted with the typical anthocyanin profile of this berry.²⁴⁻²⁶ Therefore, 134 in order to fully confirm the presence of peonidin derivatives in elderberry, a targeted MS³ experiment was conducted. Chromatographic and MS² data for compounds **5** and **6** (Table 1) were 135

in agreement with the evidence reported by Olejnik et al.²³ The fragmentation pattern of both aglycones (MS² ion fragment at m/z 301) accounted for a sole MS³ ion fragment at m/z 286 (Supplementary Figure S2), corresponding to the loss of the methyl moiety present on the B-ring of the peonidin aglycone. These data confirmed the presence of peonidin glycosides in elderberry extracts.

141

142	Table 1: Monitored	compounds in co	ell culture samples.
-----	--------------------	-----------------	----------------------

ID	Compound	RT (min)	Parent Ion (m/z)	S- Lens	Quantifier Product Ion (m/z)	CE (V)	Qualifier Product Ion (m/z)	CE (V)	MS ² Fragments	STD
			[M]⁺							
1	Cyanidin-3,5-diglucoside	1.84	611	108	287	32				3
2	Cyanidin-3-sambubioside-5-glucoside	1.90	743	108	287	32				3
3	Cyanidin-3-glucoside	3.49	449	108	287	32				3
4	Cyanidin-3-sambubioside	3.56	581	108	287	32				3
5	Peonidin-3-glucoside	3.83	463	108	301	32				3
6	Peonidin-3-sambubioside	3.83	595	108	301	32				3
			[M-H] [.]							
7	Catechol	0.90	109	68	108	20	81	20		8
8	Pyrogallol	0.99	125	68	124	24	97	15		8
9	3,4-Dihydroxybenzoic acid (Protocatechuic acid)	1.46	153	64	109	20	108	27		9
10	3,4-Dihydroxybenzaldehyde	2.06	137	80	108	30	92	30		10
11	2-(3',4'-Dihydroxyphenyl)acetic acid	2.22	167	60	123	17				N.F.
12	4-Hydroxybenzoic acid	2.41	137	70	93	16	91	5		N.F.
13	2-(4'-Hydroxyphenyl)acetic acid	2.58	151	51	107	12				13
14	acid (Homovanillic acid)	2.76	181	64	137	24	122	30		N.F.
15	4-Hydroxybenzyl alcohol	3.00	123	80	105	30	77	30		N.F.
16	3-Hydroxybenzoic acid	3.22	137	70	93	16	45	5		N.F.
17	4-Hydroxybenzaldehyde	3.22	121	80	92	30	108	30		N.F.
18	3,4-Dihydroxycinnamic acid (Caffeic acid)	3.46	179	62	135	19	134	28		30
19	4-Methoxybenzaldehyde	3.47	135	80	106	30	79	30		19
20	4-Hydroxy-3-methoxy benzoic acid (Vanillic acid)	3.55	167	60	123	17	152	18		14
21	2-(2'-Hydroxyphenyl)acetic acid	3.62	151	51	107	12			107, 123	13
22	2,4,6-Trihydroxybenzaldehyde (Phloroglucinaldehyde)	3.84	153	80	83	30	151	30		17

23	N.I.	3.85	151	51	107	12			107, 83	26
24	3-(3',4'-Dihydroxyphenyl)propanoic acid (Dihydrocaffeic acid)	3.95	181	64	137	14	119	13		N.F.
25	3-(3'-Hydroxyphenyl)propionic acid	4.22	165	48	119	20	121	15		26
26	4-Hydroxycinnamic acid (p-Coumaric acid)	4.22	163	62	119	19	93	38		30
27	4-Hydroxy-3,5-dimethoxybenzoic acid (Syringic acid)	4.30	197	70	182	20	153	26		N.F.
28	3-(4'-Hydroxy-3'- methoxyphenyl)propanoic acid (Dihydroferulic acid)	4.35	195	73	136	21	151	22		14
29	3-Hydroxycinnamic acid (<i>m</i> -Coumaric acid)	4.52	163		119		93			N.F.
30	3-Hydroxy-4-methoxy-benzoic acid (Isovanillic acid)	4.55	167	60	123	17	152	18	152, 123, 108	9
31	N.I.	4.71	151	51	107	12			107	26
32	N.I.	4.94	137	70	93	16	91	5	93	16
33	4-Hydroxy-3-methoxycinnamic acid (Ferulic acid)	4.96	193	71	134	19	178	18		30
34	3-Hydroxy-4-methoxycinnamic acid (Isoferulic acid)	5.00	193	71	134	19	178	18		N.F.
35	4-Hydroxy-3,5-dimethoxycinnamic acid (Sinapic acid)	5.30	223	94	179	31	208	25		N.F.
36	N.I.	5.94	181	64	137	24	122	30	137	14

Legend: N.I., not identified. These N.I. compounds were observed while analyzing other compounds with the same molecular and fragments ions; they were not identified when subjected to MS² analysis (MS² fragments) and in comparison to other commercially available isomers. They were quantified using the most similar standard according to their molecular weight and their putative structure. N.F., Not Found; STD means the available standard compound used for quantification.

149

Quantitative data indicated that cyanidin glycosides accounted for the majority (99%) of the 150 151 anthocyanins in the elderberry extract (Table 2). Considering the 0-day time point, elderberry 152 extract compounds 3 and 4 presented concentrations about 6- and 18-fold higher than compounds 153 2 and 1. These data are in agreement with previous studies characterizing the anthocyanin profile of elderberry fruits.^{25,26} Peonidin derivatives accounted for 1% of the anthocyanin profile, in line 154 with previous data.²³ Univariate analyses evidenced several statistically significant differences in the 155 concentration of the 25 compounds detected both among the control medium and the three gut 156 microbiota strains, and among the different collection time points (Table 2). 157

Table 2: (Poly)phenol concentration after incubations of cultures or uninoculated control medium. Different lowercase letters indicate statistically significant differences (p < 0.05) among treatments, at the same incubation time, for each compound; while different uppercase letters account for differences within treatment at different time points.

ID		CONTROL (μmol/L)		Entero	bacter cancerog (μmol/L)	enous	Bifi	dobacterium den (μmol/L)	ntium	Ĺ	ena	
	0 day	1 day	4 day	0 day	1 day	4 day	0 day	1 day	4 day	0 day	1 day	4 day
1	14.8±0.9 aA	9.7±0.9 aB	7.7±0.7 aB	13.6±1.7 aA	10.9±1.2 aAB	6.7±0.0 bB	9.9±0.6 bA	1.3±0.1 bB	0.0±0.0 dC	14.8±0.1 aA	10.4±0.8 aB	4.6±0.5 cC
2	46.6±2.6 aA	31.7±3.6 aB	29.3±1.8 aB	42.6±5.0 aA	35.0±3.2 aA	27.6±1.9 aB	31.0±0.1 bA	4.6±0.5 bB	0±0 bC	46.1±3.6 aA	34.0±2.5 aB	23.3±2.3 aC
3	272.0±4.5 abA	226.4±9.6 aB	185.5±11.4 aC	268.5±23.1 abA	181.6±14.7 bB	67.8±2.1 bC	234.6±7.5 bA	36.6±4.1 cB	0.3±0.04 dC	277.2±2.1 aA	206.2±19.7 abB	47.7±4.5 cC
4	242.3±5.2 aA	216.6±6.7 aB	199.8±10.5 aB	231.2±33.5 aA	159.9±18.2 bA	64.3±0.4 cB	215.8±6.4 aA	207.4±23.8 abA	99.8±14.2 bB	246.5±2.8 aA	202.2±15.6 abB	71.6±8.7 bcC
5	1.0±0.1 aA	0.6±0.0 aB	0.5±0.1 aB	1.0±0.1 aA	0.5±0.1 aB	0.2±0.0 bB	0.7±0.1 aA	0.1±0.0 bB	0.0±0.0 cB	1.0±0.0 aA	0.6±0.1 aB	0.2±0.0 bC
6	0.3±0.0 aA	0.2±0.0 aB	0.2±0.0 aB	0.3±0.0 aA	0.2±0.0 aAB	0.2±0.0 aA	0.2±0.0 aB	0.3±0.0 aA	0.1±0.0 bC	0.3±0.0 aA	0.2±0.0 aB	0.1±0.0 bC
7	9.2±0.3 aAB	8.9±0.7 abB	10.3±0.3 bA	8.0±0.8aA	6.9±0.2 cA	0.0±0.0 dB	8.0±0.0 aB	9.5±1.0 aA	11.4±0.8 aA	8.5±0.1 aA	7.5±0.6 bcA	7.9±0.5 cA
8	0.0±0.0	0.0±0.0 b	0.0±0.0 b	0.0±0.0 cC	1.1±0.0 aB	1.8±0.1 aA	0.0±0.0	0.0±0.0 b	0.0±0.0 b	0.0±0.0	0.0±0.0 b	0.0±0.0 b
9	11.5±0.9 aB	11.2±0.9 cB	15.7±1.5 bA	11.3±1.6 aA	6.6±0.9 dB	4.4±0.4 cB	11.0±0.4 aB	25.1±3.2 bA	21.2±3.2 bA	11.9±0.5 aB	39.7±3.3 aA	42.7±3.3 aA
10	0.3±0.1 aB	0.4±0.1 cB	0.6±0.1 bA	0.4±0.1 aC	0.7±0.1 bB	1.0±0.0 aA	0.4±0.0 aB	0.9±0.1 abA	0.9±0.1 aA	0.4±0.0 aB	1.2±0.1 aA	1.3±0.2 aA
13	0.0±0.0	0.0±0.0 b	0.0±0.0b	0.0±0.0	0.0±0.0 b	0.0±0.0 b	0.0±0.0 aA	7.5±1.0 aB	8.1±0.02 aA	0.0±0.0	0.0±0.0 b	0.0±0.0 b
18	42.7±3.4 aB	47.3±3.1 cB	69.9±7.6 cA	45.7±5.2 aA	18.7±1.9 dB	7.9±0.9 dB	39.8±2.9 aC	84.7±7.4 bB	111.6±4.0 bA	46.9±0.5 aB	2153.5±301. 8 aA	2240.2±309.9 aA
19	0.0±0.0	0.0±0.0 b	0.0±0.0 b	0.0±0.0	0.0±0.0 b	0.0±0.0 b	0.0±0.0 B	0.0±0.0 bB	0.1±0.01 bA	0.0±0.0 B	1.6±0.2 aA	1.9±0.2 aA
20	276.7±31.3 aA	190.2±24.5 aB	210.9±22.7 aAB	273.7±7.8 aA	0.0±0.0 bB	0.0±0.0 bB	0.0±0.0 b	0.0±0.0 b	0.0±0.0 b	232.8±33.3 aA	0.0±0.0 bB	0.0±0.0 bB
21	4.9±0.2 aAB	3.9±0.6 aB	6.2±0.6 bA	4.7±0.6 aA	4.5±0.6 aA	5.9±0.8 bA	3.7±0.5 aB	3.6±0.5 aB	8.0±0.6 aA	4.4±0.4 aA	3.7±0.3 aA	4.8±0.7 bA
22	0.9±0.1 bC	3.4±0.5 cB	8.9±0.6 aA	0.8±0.1 bC	2.4±0.2 dB	4.7±0.5 bA	3.9±0.3 aC	19.9±2.2 aA	9.3±0.7 aB	0.85±0.1 bC	6.7±0.7 bB	11.9±1.6 aA
23	0.0±0.0 cC	2.5±0.3 cB	5.8±0.7 aA	0.0±0.0 cA	1.9±0.2 cB	3.1±0.3 bC	2.6±0.2 aC	12.3±1.3 aA	5.9±0.6 aB	1.3±0.2 bC	4.3±0.3 bB	6.8±0.7 aA
25	1.6±0.2 bA	1.2±0.2 dA	1.2±0.1 dA	1.4±0.1 bB	2.6±0.4 bA	3.3±0.1 bA	3.1±0.2 aC	6.1±0.7 aB	44.5±3.4 aA	1.9±0.2 bA	1.8±0.1 cA	2.0±0.2 cA
26	2.4±0.2 abAB	2.2±0.2 bB	2.9±0.3 bA	1.6±0.3 bA	0.9±0.04 cB	1.1±0.1 cAB	2.8±0.2 aC	4.3±0.4 aB	6.1±0.5 aA	2.2±0.3 abB	4.02±0.5 aA	4.9±0.4 aA
28	53.6±6.55 bcB	97.8±13.2 cA	82.9±8.1 cA	43.0±6.7 cC	106.3±14.2 cB	223.1±23.7 bA	266.9±19.8 aC	1424.9±134.3 aA	720.1±69.7 aB	62.1±5.8 bC	315.4±35.1 bB	742.0±70.0 aA
30	0.2±0.0 aB	0.3±0.0 aD	0.2±0.0 aD	0.2±0.0 cA	4.4±0.4 bA	9.8±0.3 aA	4.0±0.2 bB	27.8±4.7 aC	34.9±2.8 aC	0.2±0.0 cB	6.3±0.6 bB	17.6±1.6 aB
31	0.0±0.0	0.0±0.0 b	0.0±0.0 b	0.0±0.0 C	11.0±0.4 aB	6.4±0.6 aA	0.0±0.0	0.0±0.0 b	0.0±0.0 b	0.0±0.0	0.0±0.0 b	0.0±0.0 b

32	206.7±21.5 aAB	164.7±7.7 cB	218.5±23.8 bA	196.2±26.2 aA	226.9±32.9 bA	221.2±11.0 bA	168.9±6.8 аВ	341.5±36.6 aA	457.6±41.5 aA	193.7±12.7 aA	166.7±21.4 bcA	164.6±19.3 bA
33	1.7±0.2 aA	1.2±0.1 aB	1.1±0.1 aB	1.6±0.2 aA	1.2±0.1 aB	1.2±0.1 aB	1.2±0.1 aA	1.4±0.2 aA	1.2±0.1 aA	1.7±0.1 aA	1.3±0.1 aB	1.0±0.1 aB
36	0.0±0.0	0.0±0.0 b	0.0±0.0 b	0.0±0.0	0.0±0.0 b	0.0±0.0 b	0.0±0.0	0.0±0.0 b	0.0±0.0 b	0.0±0.0 B	140.2±15.2 aA	117.2±9.5 aA
Data	are expresse	ed as mean ±	SD of three i	ndependent r	neasurements	5.						

176 Notably, lower anthocyanin concentrations (for compounds 1, 2, 3, and 5) were measured in BD cultures compared to control medium, EC, and DL cultures at the 1- and 4-day collection points, as 177 well as for compound **4** in comparison to EC and the control medium at 4-day collection point. 178 Among the phenolic acids changing during the incubation period, protocatechuic (9) and caffeic (18) 179 180 acids were significantly higher in DL compared to BD, control medium, and EC cultures after 4-days 181 incubation. Unknown compound 32 showed higher concentrations at 1-day and 4-day after BD 182 incubation with respect to EC, control, and DL incubations. Last, some compounds like 3-(3'hydroxyphenyl)propionic acid (25), p-coumaric acid (26) and ferulic acid (33) evidenced slight 183 differences among time points for some treatments as well as among treatments for some collection 184 points (Table 2). 185

A multivariate PCA was carried out to better understand the variability in the metabolic pathway of 186 187 anthocyanin degradation for each gut microbial strain (Figure 1). Three principal components (PCs) explained up to 83.5% of the total variability. PC1 accounted for 39.9% of the observed variability 188 and was positively loaded from some phenolics (13, 22, 23, 25, 26, 32, and 28), while negatively 189 190 loaded from most of the anthocyanins (1, 2, 3, and 5) (Figure 1A, 1B). PC2 explained 23.4% of the total variability and had positive loadings from protocatechuic acid (9), caffeic acid (18), 191 192 methoxybenzaldehyde (19), and compound 36 (Figure 1A). PC3 accounted for 20.2% of the observed variability and was mostly loaded positively from catechol (7) and the anthocyanin 193 194 sambubioside (4 and 6), whereas negatively from pyrogallol (8) and compound 31 (Figure 1B). 195 Individual scores for each gut bacteria strain and time point revealed interesting insights with regard 196 to the putative degradation pathways of anthocyanins, as compared to the control media (Figures 197 1C and 1D). BD-mediated anthocyanin degradation was related to PC1 loads and, thus, to an extensive catabolism of anthocyanins and to increasing amounts of monohydroxylated phenolics 198 199 (13, 25, and 26) and C6-C3 backbones (25, 26, and 28) along the 4-day incubation. DL metabolism,

associated with positive scores for PC2, entailed a mild degradation of the anthocyanin fraction but
a high production of dihydroxylated phenolic acids (9 and 18) and C6-C1 scaffolds (9 and 19). EC
catabolism, linked mainly to PC3 scores, accounted for an increasing production of pyrogallol (8)
and an intense metabolism of catechol (7), as opposed to the rest of the bacterial strains, which did
not evidence degradation pathways related to these two phenols.



Figure 1. Loading plots (A, C) and score plots (B, D) of the first three PCs obtained from the PCA with varimax of the considered phenolic metabolites and bacterial strains activity. Legend: CTR, control cell medium; BD, *Bifidobacterium dentium*; DL *Dorea longicatena*; EC, *Enterobacter cancerogenous*; PC, principal component. Numbers close to control medium and bacteria acronyms (0, 1 and 4) indicate the days of the medium samples collection after incubation with anthocyanins. The legend relative to the phenolic metabolite numbers is available in **Table 1**.

- 212
- 213

214 The microbial degradation of anthocyanins may follow several different pathways, as reported in previous in vivo and in vitro studies,^{15,18,22} and this aspect highly influences anthocyanin 215 bioavailability. Following the pattern described by González-Barrio et al. for raspberry anthocyanins 216 incubated with human fecal suspensions,¹⁵ our results suggested that only EC was able to degrade 217 cyanidin derivatives to yield pyrogallol (8) but not catechol (7), which was completely degraded. 218 Cyanidin can also be degraded by releasing protocatechuic acid (9),¹⁵ which increased along the 219 incubation time in BD and DL, while it decreased in EC. In this sense, De Ferrars et al.¹⁸ reported a 220 decreasing trend for protocatechuic acid amounts in fecal samples collected for 2 days after 221 supplementation of human volunteers with ¹³C₅-labelled cyanidin-3-glucoside. Regarding caffeic 222 acid (18), a key intermediate of anthocyanin degradation,²² it showed a very significant increment 223 224 when elderberry extract was incubated with DL, with a moderate increase registered also for BD. Dihydroferulic acid (28) also increased notably in presence of the three tested inocula, while ferulic 225 acid (33) was not a relevant metabolite. De Ferrars et al.¹⁸ evidenced similar results for caffeic acid 226 in fecal samples of volunteers supplemented with ¹³C₅-labelled cyanidin-3-glucoside, but they 227 recovered very high amounts of ferulic acid and not of dihydroferulic acid, although the 228 dehydrogenation of the double bond has been previously hypothesized in the potential microbial 229 metabolic pathways of cyanidin-based anthocyanin.¹⁴ The microbial degradation of cyanidin also led 230 to the formation of phloroglucinaldehyde (22),¹⁸ while in our study this compound increased for EC 231 and DL along the 4-day incubation, remaining stable after BD incubation. Moreover, 232 phloroglucinaldehyde has found to be metabolized to methoxybenzaldehyde (19),¹⁸ a pathway that 233 was confirmed mainly for DL and just scarcely for BD, while it was not found for EC. Concerning 3,4-234 235 dihydroxybenzaldehyde (10), an aldehyde putatively derived from protocatechuic acid, it increased for all the tested strains, as did 3-(3'-hydroxyphenyl)propionic acid (25).¹⁸ 236

237 To better describe the metabolic transformations carried out by each bacterial strain, efforts were made to identify the unexpected metabolites. Compound **32** ($[M-H]^{-}$ at m/z 137) was hypothesized 238 to be 2-hydroxybenzoic acid, as it might be formed from phloroglucinaldehyde following the 239 pathway reported by De Ferrars et al.¹⁸ and leading to 2-hydroxy-4-methoxybenzaldehyde 240 formation. This same metabolic pathway may also be linked with the presence of 2-(2'-241 242 hydroxyphenyl)acetic acid (21). Similarly, compound 36 ($[M-H]^{-}$ at m/z 181), which was only present 243 in DL samples, was hypothesized to be 2-(3'-hydroxy-4'-methoxyphenyl)acetic acid (aka homoisovanillic acid) since its retention time and fragment ions did not match with those of other 244 degradation,^{15,18,22} isomers expected somehow from cyanidin 3-(3',5'-245 like dihydroxyphenyl)propionic 3-(2',4'-dihydroxyphenyl)propionic 246 acid, acid, and 3-(4'-247 hydroxyphenyl)lactic acid. Compound **36** might be related to the degradation pathways yielding other 3'-hydroxy-4'-methoxyphenyl structures (i.e., isovanillic acids).^{15,18,22} Structure for compound 248 **30** ([M-H]⁻ at m/z 167) did not match with the analytical features of the isomers labelled as putative 249 metabolites (i.e., 2-hydroxy-4-methoxyphenylbenzoic acid, 3-hydroxymandelic acid, 2-(2',4'-250 dihydroxyphenyl)acetic acid and 2-(3',5'-dihydroxyphenyl)acetic acid), but based on its MS² 251 fragmentation pattern it has been identified as 3-hydroxy-4-methoxy-benzoic acid (isovanillic acid). 252 253 On contrary, no one of the 2 parent ions $[M-H]^{-}$ at m/z 151 (23 and 31) could be assigned to an 254 isomer of 4-hydroxyphenylacetic acid (13) or to a methoxybenzoic acid taking into account their 255 retention times and fragmentation patterns.

The interplay between anthocyanin catabolism by the gut microbiota and the microbial modulation caused by anthocyanin consumption is well-known.²⁷ But, despite the different capability to metabolize anthocyanins of the three bacterial species assessed, there is no information linking them to differences in the phenolic metabolism of anthocyanin-rich sources. A previous report²⁸ demonstrated that *Clostridium saccharogumia* DSM 17460 and *Eubacterium ramulus* DSM 16296 261 have a different capability to degrade cyanidin-3-glucoside. The metabolic pathways related to these two bacterial strains were different from those observed when this compound was incubated 262 *in vitro* with human fecal slurries.²⁸ Incubation of cyanidin-rutinoside with human gut microbiota led 263 to a marked increase of *Bacteroides*, while a limited bifidogenic effect.²⁹ Nevertheless, high levels 264 of Bifidobacteria have been associated with increased levels of anthocyanin-derived microbial 265 catabolites upon consumption of red wine.³⁰ It has been recently hypothesized that differences in 266 the metabolism of anthocyanins could be related to the gut microbiota composition of each 267 individual and, in particular, to the relative abundance of *Bacteroides*.²⁹ However, to date, there is 268 a lack of information on the inter-individual differences in the production of anthocyanin-derived 269 metabolites by specific gut microbiota strains or by specific enterotypes. This work contributed 270 271 hence to gain insights in the different pathways that may occur in gut microbiota-mediated 272 anthocyanin metabolism.

A point worth mentioning is the confirmation of the presence of peonidin glycosides in elderberry 273 extracts, in line with Olejnik et al.²³ The two peonidin derivatives identified have been previously 274 identified in urine samples of volunteers consuming elderberry extracts.^{21,31} Their presence in 275 circulation upon consumption of elderberry has been related to the 3'-O-methylation of cyanidin 276 derivatives, not affecting the glycosylation pattern of the anthocyanin.^{21,31} However, this novel 277 278 evidence on elderberry composition leaves the door open to hypothesize that not all the peonidin 279 glycosides found in circulation are the result of cyanidin metabolism. Actually, the presence of peonidin glycosides in circulation upon consumption of elderberry extracts could be partially 280 associated with the direct absorption of these compounds at gastrointestinal level, without further 281 282 methylation. Further work is thus required to fully understand the metabolic reactions occurring at 283 human level to elderberry anthocyanins and, in particular, to cyanidin glycosides.

284 In conclusion, the present study highlighted a considerable variability in the type and in the concentration of the anthocyanin degradation products among three gut bacterial strains. These 285 findings support the idea that the presence of certain strains as well as the ecological competition 286 among them are key factors at the basis of the inter-individual variability in anthocyanin 287 bioavailability. Further studies are required in order to fully elucidate the degradation pathways of 288 289 the most representative bacterial species and their relation to different gut microbiome 290 compositions. Moreover, the effect of the food matrix or other sources of anthocyanins on the 291 catabolism by individual bacterial strains of anthocyanins should be further explored.

292

293 ABBREVIATIONS USED

BD, *Bifidobacterium dentium*; DL, *Dorea longicatena*; EC, *Enterobacter cancerogenous*; PC, principal
 component; PCA, principal component analysis.

296

297 SUPPORTING INFORMATION DESCRIPTION

298 **Supplementary Table S1.** MML medium composition.

299 **Supplementary Figure S1.** Protocatechuic acid (PCA) production/degradation following elderberry

300 anthocyanin metabolism by different gut microbiota strains or inoculated controls.

301 **Supplementary Figure S2.** Chromatograms and MS³ fragment ion spectra of peonidin glycosides.

- 302 **Supplementary Method S1.** Detailed description of the analytical method used for the identification
- 303 of peonidin glycosides.

304

305 **REFERENCES**

306 (1) Kay, C. D.; Kroon, P. A.; Cassidy, A. The Bioactivity of Dietary Anthocyanins Is Likely to Be

307 Mediated by Their Degradation Products. *Mol. Nutr. Food Res.* **2009**, *53* (SUPPL. 1), 92–101.

- 308 (2) Del Rio, D.; Rodriguez-Mateos, A.; Spencer, J. P. E.; Tognolini, M.; Borges, G.; Crozier, A.
- 309 Dietary (Poly)Phenolics in Human Health: Structures, Bioavailability, and Evidence of
- 310 Protective Effects Against Chronic Diseases. *Antioxid. Redox Signal.* **2013**, *18* (14), 1818–
- 311 1892.
- Welch, C. R.; Wu, Q.; Simon, J. E. Recent Advances in Anthocyanin Analysis and
 Characterization. *Curr. Anal. Chem.* **2009**, *4* (2), 75–101.
- 314 (4) Mena, P.; Domínguez-Perles, R.; Gironés-Vilaplana, A.; Baenas, N.; García-Viguera, C.;
- Villaño, D.; Rodriguez-Mateos, A.; Vauzour, D.; Krueger, C. G.; Shanmuganayagam, D.; et al.
- Flavan-3-Ols, Anthocyanins, and Inflammation. *IUBMB Life* **2014**, *66* (11), 745–758.
- 317 (5) Cassidy, A.; Mukamal, K. J.; Liu, L.; Franz, M.; Eliassen, A. H.; Rimm, E. B. High Anthocyanin
- Intake Is Associated with a Reduced Risk of Myocardial Infarction in Young and Middle-Aged
 Women. *Circulation* 2013, *127* (2), 188–196.
- 320 (6) Tresserra-Rimbau, A.; Rimm, E. B.; Medina-Remón, A.; Martínez-González, M. A.; de la
- 321 Torre, R.; Corella, D.; Salas-Salvadó, J.; Gómez-Gracia, E.; Lapetra, J.; Arós, F.; et al. Inverse
- 322 Association between Habitual Polyphenol Intake and Incidence of Cardiovascular Events in
- 323 the PREDIMED Study. *Nutr. Metab. Cardiovasc. Dis.* **2014**, *24* (6), 639–647.
- 324 (7) Goetz, M. E.; Judd, S. E.; Safford, M. M.; Hartman, T. J.; McClellan, W. M.; Vaccarino, V.
- 325 Dietary Flavonoid Intake and Incident Coronary Heart Disease: The REasons for Geographic
- and Racial Differences in Stroke (REGARDS) Study. Am. J. Clin. Nutr. 2016, 104 (5), 1236–
- 327 1244.
- 328 (8) Kuntz, S.; Kunz, C.; Herrmann, J.; Borsch, C. H.; Abel, G.; Fröhling, B.; Dietrich, H.; Rudloff, S.
- 329 Anthocyanins from Fruit Juices Improve the Antioxidant Status of Healthy Young Female
- 330 Volunteers without Affecting Anti-Inflammatory Parameters: Results from the Randomised,
- 331 Double-Blind, Placebo-Controlled, Cross-over ANTHONIA (ANTHOcyanins in Nutrition). Br. J.

332 *Nutr.* **2014**, *112* (6), 925–936.

- 333 (9) Del Bo', C.; Martini, D.; Porrini, M.; Klimis-Zacas, D.; Riso, P. Berries and Oxidative Stress
 334 Markers: An Overview of Human Intervention Studies. *Food Funct.* 2015, 6 (9), 2890–2917.
- 335 (10) Kent, K.; Charlton, K. E.; Netzel, M.; Fanning, K. Food-Based Anthocyanin Intake and
- Cognitive Outcomes in Human Intervention Trials: A Systematic Review. J. Hum. Nutr. Diet.
 2017, 30 (3), 260–274.
- 338 (11) Kent, K.; Charlton, K.; Roodenrys, S.; Batterham, M.; Potter, J.; Traynor, V.; Gilbert, H.;
- 339 Morgan, O.; Richards, R. Consumption of Anthocyanin Rich Cherry Juice for 12 Weeks
- 340 Improves Memory and Cognition in Older Adults with Mild to Moderate Dementia. *Eur. J.*
- 341 *Nutr.* **2015**, *56* (1), 333–341.
- González-Barrio, R.; Borges, G.; Mullen, W.; Crozier, A. Bioavailability of Anthocyanins and
 Ellagitannins Following Consumption of Raspberries by Healthy Humans and Subjects with
 an Ileostomy. J. Agric. Food Chem. 2010, 58 (7), 3933–3939.
- 345 (13) Fang, J. Bioavailability of Anthocyanins. Drug Metab. Rev. 2014, 46 (4), 508–520.
- 346 (14) Ludwig, I. A.; Mena, P.; Calani, L.; Borges, G.; Pereira-Caro, G.; Bresciani, L.; Del Rio, D.; Lean,
- M. E. J.; Crozier, A. New Insights into the Bioavailability of Red Raspberry Anthocyanins and
 Ellagitannins. *Free Radic. Biol. Med.* 2015, *89*, 758–769.
- 349 (15) Gonzalez-Barrio, R.; Edwards, C. a; Crozier, A. Colonic Catabolism of Ellagitannins, Ellagic
- Acid, and Raspberry Anthocyanins: In Vivo and In Vitro Studies. *Drug Metab. Dispos.* 2011,
 39 (9), 1680–1688.
- 352 (16) Ávila, M.; Hidalgo, M.; Sánchez-Moreno, C.; Pelaez, C.; Requena, T.; Pascual-Teresa, S. de.
- 353 Bioconversion of Anthocyanin Glycosides by Bifidobacteria and Lactobacillus. *Food Res. Int.*

2009, *42* (10), 1453–1461.

355 (17) Keppler, K.; Humpf, H. U. Metabolism of Anthocyanins and Their Phenolic Degradation

356		Products by the Intestinal Microflora. <i>Bioorganic Med. Chem.</i> 2005, 13 (17), 5195–5205.
357	(18)	De Ferrars, R. M.; Czank, C.; Zhang, Q.; Botting, N. P.; Kroon, P. A.; Cassidy, A.; Kay, C. D. The
358		Pharmacokinetics of Anthocyanins and Their Metabolites in Humans. Br. J. Pharmacol. 2014,
359		171 (13), 3268–3282.
360	(19)	Sala, R.; Mena, P.; Savi, M.; Brighenti, F.; Crozier, A.; Miragoli, M.; Stilli, D.; Del Rio, D.
361		Urolithins at Physiological Concentrations Affect the Levels of Pro-Inflammatory Cytokines
362		and Growth Factor in Cultured Cardiac Cells in Hyperglucidic Conditions. J. Funct. Foods
363		2015 , <i>15</i> , 97–105.
364	(20)	Brindani, N.; Mena, P.; Calani, L.; Benzie, I.; Choi, S. W.; Brighenti, F.; Zanardi, F.; Curti, C.;
365		Del Rio, D. Synthetic and Analytical Strategies for the Quantification of Phenyl- γ -
366		Valerolactone Conjugated Metabolites in Human Urine. Mol. Nutr. Food Res. 2017, 61 (9),
367		6–10.
368	(21)	De Ferrars, R. M.; Cassidy, A.; Curtis, P.; Kay, C. D. Phenolic Metabolites of Anthocyanins
369		Following a Dietary Intervention Study in Post-Menopausal Women. Mol. Nutr. Food Res.
370		2014 , <i>58</i> (3), 490–502.
371	(22)	Kay, C. D.; Pereira-Caro, G.; Ludwig, I. A.; Clifford, M. N.; Crozier, A. Anthocyanins and
372		Flavanones Are More Bioavailable than Previously Perceived: A Review of Recent Evidence.

373 Annu. Rev. Food Sci. Technol. **2017**, 8 (1), 155–180.

374 (23) Olejnik, A.; Olkowicz, M.; Kowalska, K.; Rychlik, J.; Dembczyński, R.; Myszka, K.; Juzwa, W.;

Białas, W.; Moyer, M. P. Gastrointestinal digested Sambucus nigra L. fruit extract protects in

vitro cultured human colon cells against oxidative stress. *Food Chem.* **2016**, *197*, 648-657.

377 (24) González-Molina, E.; Gironés-Vilaplana, A.; Mena, P.; Moreno, D. A.; García-Viguera, C. New

378 Beverages of Lemon Juice with Elderberry and Grape Concentrates as a Source of Bioactive

379 Compounds. J. Food Sci. **2012**, 77, C727-C733.

- 380 (25) Mikulic-Petkovsek, M.; Veberic, R.; Todorovic, B.; Slatnar, A.; Stampar, F.; Schmitzer, V.;
- Ivancic, A. Investigation of Anthocyanin Profile of Four Elderberry Species and Interspecific
 Hybrids. J. Agric. Food Chem. 2014, 62 (24), 5573–5580.
- 383 (26) Senica, M.; Stampar, F.; Veberic, R.; Mikulic-Petkovsek, M. The Higher the Better?
- Differences in Phenolics and Cyanogenic Glycosides in Sambucus Nigra Leaves, Flowers and
 Berries from Different Altitudes. J. Sci. Food Agric. 2017, 97 (8), 2623–2632.
- (27) Jamar, G.; Estadella, D.; Pisani, L. P. Contribution of anthocyanin-rich foods in obesity
 control through gut microbiota interactions. *BioFactors* 2017, 43, 507-516.
- 388 (28) Hanske, L.; Engst, W.; Loh, G.; Sczesny, S.; Blaut, M.; Braune, A. Contribution of gut bacteria
- to the metabolism of cyanidin 3-glucoside in human microbiota-associated rats. *Br. J. Nutr.*2013, *109*, 1433-1441.
- 391 (29) Mayta-Apaza, A. C.; Pottgen, E.; De Bodt, J.; Papp, N.; Marasini, D.; Howard, L.; Abranko, L.;
- 392 Van de Wiele, T.; Lee, S. O.; Carbonero, F. Impact of tart cherries polyphenols on the human
- 393 gut microbiota and phenolic metabolites in vitro and in vivo. J. Nutr. Biochem. 2018, 59,
- **394 160-172**.
- 395 (30) Boto-Ordonez, M.; Urpi-Sarda, M.; Queipo-Ortuno, M. I.; Tulipani, S.; Tinahones, F. J.;
- 396 Andres-Lacueva, C. High levels of Bifidobacteria are associated with increased levels of
- 397 anthocyanin microbial metabolites: a randomized clinical trial. *Food Funct.* **2014**, *5*, 1932-
- **398 1938**.
- Wu, X.; Cao, G.; Prior, R. L. Absorption and metabolism of anthocyanins in elderly women
 after consumption of elderberry or blueberry. *J. Nutr.* 2002, *132*, 1865-1871.

401 TOC graphic

